NYU Study Reveals Gut Bacteria Predict Melanoma Recurrence with 94% Accuracy Using Microbial Fingerprints

NYU researchers find gut microbiome markers predict melanoma recurrence with 94% accuracy using geographic microbial fingerprints to guide immunotherapy.

By: AXL Media

Published: Apr 18, 2026, 10:54 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Biological Radar for Cancer Recurrence

A groundbreaking study led by NYU Langone Health and the Perlmutter Cancer Center has established a direct link between the human gut microbiome and the success of melanoma treatments. While immunotherapy and surgery are standard for skin cancer, between 25% and 40% of patients experience a recurrence of the disease. Researchers have now discovered that the trillions of bacteria residing in the digestive tract act as a predictive indicator, signaling with up to 94% accuracy whether the cancer is likely to return. This discovery provides a new clinical lens through which doctors can monitor high risk patients who might otherwise appear to be in stable remission.

The Immune System Training Ground

The gut microbiome functions as an essential training center for the body's immune defenses, teaching cells to distinguish between helpful organisms and dangerous pathogens. According to the research, specific bacterial groups, including Eubacterium, Ruminococcus, Firmicutes, and Clostridium, interact with natural killer cells and T cells to modulate the body’s response to immunotherapies. Beyond immune regulation, these bacteria may also influence the sugar supply that fuels the growth of malignant cells. By understanding these microbial interactions, scientists are beginning to decode how the internal environment of the gut can either bolster or undermine aggressive cancer treatments.

Cracking the Geographic Microbiome Code

One of the most significant hurdles in microbiome research has been the variation of bacterial species across different global populations. The NYU team analyzed data from the CheckMate 915 international clinical trial, involving 674 patients across North America, Europe, Australia, and other regions. They found that while predictive markers often vary by location, accuracy remains high when patients are matched based on their overall "microbial fingerprint" rather than just their country of origin. Jiyoung Ahn, PhD, a professor at NYU Grossman School of Medicine, explained that while past studies struggled with regional differences, this new method proves markers are generalizable when the underlying microbiome structure is taken into account.